Actively Recruiting
Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients
Led by Ruijin Hospital · Updated on 2022-09-16
340
Participants Needed
2
Research Sites
302 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery.
CONDITIONS
Official Title
Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 80 years
- Histologically confirmed cervical cancer, FIGO stage Ia2 to IIb, with no prior chemotherapy or radiotherapy
- Radical hysterectomy performed 3 to 4 weeks before enrollment
- Karnofsky performance score greater than 70
- Postoperative pathology showing at least one intermediate-risk factor: (1) lympho-vascular space invasion (LVSI+) with deep one-third stromal invasion; (2) LVSI(+) with middle one-third stromal invasion and tumor size 64 cm; or (3) non-squamous cell carcinoma
- No contraindications to radiation or chemotherapy based on examination results
- Willingness to accept treatment
- Ability to comply with trial requirements
You will not qualify if you...
- Presence of postoperative residual tumor
- Postoperative recurrence or metastasis
- Pelvic lymph node metastasis
- Parametrial invasion
- Positive surgical margins
- No lymph node dissection performed
- Postoperative pathology showing aortic lymph node metastasis
- Examination results indicating contraindications to radiotherapy
- No indications for radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Ruijin Hospital, Shanghai jiaotong univestigy school of medicine
Shanghai, Shanghai Municipality, China, 200025
Not Yet Recruiting
2
Ruijin Hospital, Shanghai jiaotong univestigy school of medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
W
Wei-Xiang Qi, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here